Holen Sie sich die Stockscreener-App
0.775
6.85%
-0.057
Handel nachbörslich:
.78
0.005
+0.65%
Schlusskurs vom Vortag:
$0.832
Offen:
$0.8
24-Stunden-Volumen:
568.05K
Relative Volume:
1.92
Marktkapitalisierung:
$80.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.73M
KGV:
-5.0987
EPS:
-0.152
Netto-Cashflow:
$-3.92M
1W Leistung:
-17.65%
1M Leistung:
-22.50%
6M Leistung:
-1.49%
1J Leistung:
+30.79%
1-Tages-Spanne:
$0.738
$0.831
1-Wochen-Bereich:
$0.73
$1.0722
52-Wochen-Spanne:
$0.41
$1.74
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Firmenname
Tiziana Life Sciences Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie TLSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
0.775 | 80.46M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-22 | Eingeleitet | B. Riley Securities | Buy |
| 2018-12-17 | Eingeleitet | Laidlaw | Buy |
Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten
Tiziana Life Sciences doses first Alzheimer’s patient with intranasal foralumab - Proactive Investors Australia
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab - The Manila Times
Tiziana Life Sciences Launches Novel Alzheimer's Treatment Trial with Groundbreaking Intranasal Therapy - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Drop in Short Interest - MarketBeat
3 US Penny Stocks With Market Caps Under $200M To Consider - Simply Wall St
17% Gain Today – This Stock Isn’t Done Yet - RagingBull
Tiziana Life Sciences expands Phase 2 trial for non-active SPMS - Yahoo Finance
Tiziana broadens Phase 2 trial for MS therapy By Investing.com - Investing.com Canada
Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutions - Proactive Investors Australia
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
PHLX Canadian Dollar (XDC) QuotePress Release - The Globe and Mail
TSX Industrials EW Index (TXIE) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Tiziana broadens Phase 2 trial for MS therapy - Investing.com India
S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers - The Manila Times
Tiziana Life Sciences Expands Breakthrough MS Drug Trial to Elite U.S. Medical Centers - StockTitan
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 3.7%Here's What Happened - MarketBeat
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 3.7% – Here’s What Happened - Defense World
Tiziana Life Sciences Secures ALS Trial Funding - Yahoo Finance
Tiziana Life Sciences secures grant for ALS trial - Proactive Investors USA
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association - The Manila Times
Tiziana Life Sciences Secures ALS Association Grant for Breakthrough Foralumab Trial | TLSA Stock News - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Growth in Short Interest - MarketBeat
Tiziana Life Sciences CEO discusses foralumab potential to enhance OzempicICYMI - Proactive Investors USA
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference - Proactive Investors UK
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data - The Manila Times
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer’s therapy - Proactive Investors USA
Tiziana Life Sciences Plans Share Sale with Jefferies - MSN
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million - The Manila Times
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study - GlobeNewswire
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million - GlobeNewswire Inc.
Tiziana reports progress in obesity inflammation study By Investing.com - Investing.com South Africa
Tiziana Life Sciences : announces plans for clinical development of foralumab, the company’s fully human CD3 antibody - Marketscreener.com
Tiziana Life Sciences' Semaglutide combo shows potential in obesity-related liver inflammation - Proactive Investors USA
TLSATiziana Life Sciences Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity - Proactive Investors UK
Tiziana reports progress in obesity inflammation study - Investing.com
Proactive news headlines: Helix, Hemogenyx, DEC, Ananda, Thor Energy, Bradda Head and more - Proactive Investors UK
Discover October 2024's Promising US Penny Stocks - Simply Wall St
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Tiziana Life Sciences Advances with Promising Drug Trials - Yahoo Finance
Tiziana Life Sciences reports interim results, updates on programs - Investing.com India
Finanzdaten der Tiziana Life Sciences Ltd-Aktie (TLSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):